New hope for rare genetic cancers? drug targets POLE/POLD1 mutations
NCT ID NCT03810339
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tumors or slow disease progression. About 35 adults aged 18-75 will receive the drug every 3 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab (a PD-1 antibody)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations (POLE/POLD1) and haven't responded to standard therapy.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 35 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer center of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••